Blazing Through the Evidence on THC Versus CBD Combinations in Medical Cannabinoids.

Clinical Question: Do tetrahydrocannabinol (THC), cannabidiol (CBD), or the THC/CBD combination yield differing benefits or harms?

Bottom Line: From four randomized controlled trials (RCT), one found THC/CBD superior to THC but this was inconsistent within study and with other studies. Adverse events are prevalent in THC/CBD and individual components. While some early poor-quality research in healthy users suggest CBD may attenuate some psychiatric effects of THC, better research in real patients is needed to verify any benefits of specific components.

Evidence:
Identified four RCTs comparing THC, CBD, or combined.
- RCT: 243 terminal cancer and weight loss patients, comparing THC/CBD versus THC versus placebo over six weeks.¹
  - THC/CBD versus THC: No statistical difference in appetite or adverse events.
- RCT: 177 refractory cancer pain patients on strong opioids (~270 mg morphine), comparing THC/CBD versus THC versus placebo over two weeks.²
  - ≥30% pain reduction: 38% THC/CBD versus 21% THC, Number Needed to Treat=6.
    - No difference for ≥10% or ≥50% pain reduction.
  - Adverse events: No difference with THC/CBD versus THC.
- RCT: 48 brachial nerve injury patients, comparing THC/CBD versus THC versus placebo over two weeks.³
  - Baseline pain 7.5/10: Both THC/CBD and THC groups reduced pain ~1.3 points, statistically significantly more than 0.6 with placebo.
  - Adverse events not significantly different between THC/CBD and THC.
- "N of 1" RCT: 24 chronic pain patients who benefitted from THC/CBD, compared THC/CBD versus THC versus CBD versus placebo over eight weeks.⁴
  - Patients reporting equal/better pain management versus original THC/CBD.
    - 38% THC/CBD, 33% THC, 17% CBD: Not statistically different.
Context:

- RCT 120 Dravet syndrome pediatric patients: CBD reduced seizure frequency ~22% over placebo at 14 weeks.⁵
  - Adverse events include somnolence (Number Needed to Harm (NNH)=4), diarrhea (NNH=5), and appetite loss (NNH=5).
  - Recent RCT of lennox-gastaut (seizure) syndrome adults found similar.⁶
- Canadian guideline recommends cannabinoids only in refractory neuropathic pain, palliative cancer pain, chemotherapy-associated nausea/vomiting, and spasticity.⁷
- One guideline recommends low THC or high CBD:THC ratios to diminish THC adverse events.⁸
  - Largely based on small studies of healthy volunteers (some with other drug use history) examining MRI or short-term scale changes.

Authors:
Danielle Perry BScN MSc Candidate, Joey Ton BScPharm PharmD, G. Michael Allan MD CCFP

Disclosure:
Authors do not have any conflicts of interest to declare. (Authors DP and JT are supported by the Physician Learning Program.)

References:

Tools for Practice is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practicing family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic integrity. If you are not a member of the ACFP and would like to receive the TFP emails, please sign up for the distribution list at http://bit.ly/signupfortfps. Archived articles are available on the ACFP website.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.